Corbus Pharmaceuticals Holdings, Inc.

CRBP

Corbus Pharmaceuticals Holdings, Inc.
Current price$5.165
5 days change-3.08%
CRBP intrinsic value

$15.77

+205.4%
Strong SellStrong Buy

Strong Buy

Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London

Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London

- Presentation with live audio webcast on Wednesday, November 20th at 5:20 PM DST - Norwood, MA , Nov. 12, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP).

We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business Growth

We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although. . .

Corbus Pharmaceuticals earnings report beats estimated earnings per share by 18.75%, but misses revenue by Infinity%

Corbus Pharmaceuticals earnings report beats estimated earnings per share by 18.75%, but misses revenue by Infinity%

Corbus Pharmaceuticals reported earnings per share of $-0. 32 on revenue of $null, the consensus between analysts was $-0.38 per share on revenue of $2M.

Corbus Pharmaceuticals earnings report beats estimated earnings per share by 666.67%, but misses revenue by Infinity%

Corbus Pharmaceuticals earnings report beats estimated earnings per share by 666.67%, but misses revenue by Infinity%

Corbus Pharmaceuticals reported earnings per share of $0. 03 on revenue of $null, the consensus between analysts was $-0.17 per share on revenue of $10M.

What You Need to Know About Corbus Pharmaceuticals' Q1 Earnings Update

What You Need to Know About Corbus Pharmaceuticals' Q1 Earnings Update

The clinical-stage biotech's top- and bottom-line numbers weren't the most important thing in the first quarter.

Corbus Pharmaceuticals (CRBP) to Report Q1 Results: Wall Street Expects Earnings Growth

Corbus Pharmaceuticals (CRBP) to Report Q1 Results: Wall Street Expects Earnings Growth

Corbus Pharmaceuticals (CRBP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.